Chief Scientific Officer Gary Hattersley fully exits NUVB position: 369,051 shares sold for $2.7M, reducing holdings to 0
Gary Hattersley, Chief Scientific Officer at Nuvation Bio, executed 2 separate sales totaling 369,051 shares for $2,667,131.58 on 2025-11-20, completely liquidating his holding. The blended sale price of $7.23 occurs just 18 basis points below the current price of $7.41, positioning this exit near recent highs—notably at the 52-week high. The complete exit by a senior scientific executive is noteworthy given the company's financial profile: NUVB posted net income of $-55,792,000.00 against revenue of $13,120,000.00 in the latest quarter, leaving it unprofitable. This full divestment of an officer's entire stake, combined with the company's ongoing cash burn, warrants close attention from investors evaluating management's confidence in the therapeutic pipeline and capital runway.